Sun Pharmaceuticals is the largest pharmaceutical company from India and the fifth largest specialty generic company in the world. It has capabilities across dosage forms like injectables, sprays, ointments, creams, liquids, tablets and capsules. Its businesses include producing generics, branded generics, speciality, over-the-counter (OTC) products, anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates in the full range of dosage forms. It also produces specialty APIs. US formulations contributed the most to company’s US$ 4 billion sales in FY18 with a contribution of 34 per cent, followed by India branded formulations at 31 per cent. In FY19, total income of the company reached Rs 30,091.40 crore (US$ 4.33 billion).
Company Website: www.sunpharma.com
Sun Pharma – Reaching People. Touching Lives.
| 2018 | Sales of US$ 4 billion in FY18; Announced acquisition of US-based speciality pharmaceutical company Avenue Therapeutics for US$ 215 million |
| 2017 | Agreement signed with National Institute of Virology, India to fight Zika, Chikungunya and Dengue |
| 2013 | Became world’s fifth largest specialty generic pharmaceutical company with acquisition of Ranbaxy |
| 2000 | Acquired Pradeep Drug Company |
| 1997 | First international acquisition with Caraco Pharmaceutical Laboratories, USA |
| 1996 | Sales network expanded across 24 countries |
| 1994 | Launched initial public offer (IPO) |
| 1989 | Introduced gastroenterology products in India |
| 1983 | Established with a portfolio of five psychiatry products |
Updated: May, 2019